Oslo, July 21, 2023 -RESPINOR AS, (“RESPINOR ” or the “Company”), a privately held clinical-stage medical device company focused on improving clinical decision-making in critically ill patients in the intensive care unit (ICU), announced the appointment of Anders Wold as Chair of the Board, with immediate effect.
Anders Wold started his career in the field of medical ultrasound in 1984 when he joined the start-up Vingmed which was acquired by GE Healthcare in 1998. He has nearly forty years of leadership experience in the healthcare and ultrasound industry, including President and CEO of GE Healthcare Clinical Care Solutions.
The current Chair of the Board and main shareholder Aage Bryn will assume the Board member role. The rest of the Board will continue in their current roles, Jan Fikkan as Vice Chair and Marco Renoldi, Carl Christian Gilhuus-Moe, and Otto Skolling as Board Members.
Aage Bryn, Chair of the Board, commented: “We are delighted that Anders has accepted the role of Chair of the Board. He is a perfect match for Respinor at this stage of development. He has unique knowledge of the ultrasound business as well as broad international experience and contacts within the MedTech industry. This will be extremely valuable for us when embarking on the next stage to commercialize and launch DXT on the market.”
Anders Wold stated: “I am thrilled to join RESPINOR and chair the Board. RESPINOR is at an exciting stage with an innovative platform technology, a unique ultrasound solution with a product addressing a significant unmet clinical need in the respiratory space. It will be very exciting to take this to market for support of patients undergoing critical ventilation.
In addition, the platform technology is set for several new applications. It is striking to discover the potential and how this may have many familiar similarities to how we created and evolved the global ultrasound industry.“
RESPINOR AS is a privately-owned medical device company founded in Oslo, Norway, in 2015 and established as a holding company RESPINOR AB (publ) in Stockholm, Sweden in 2022. The Company is developing a novel, non-invasive, ultrasound-based medical device, RESPINOR DXT (Diaphragm Excursion Technology) for continuous monitoring of the diaphragm, our main breathing muscle, to improve clinical decision-making in critically ill patients in the intensive care unit (ICU). This is the first ultrasound sensor that can be attached directly to the patient’s skin for early detection of diaphragm dysfunction (DD) and continuous monitoring of diaphragm function. The technology has a wide range of potential benefits in several clinical areas. The Company’s technology is the winner of Horizon 2020 financing, both in phase I and II, and the Nordic Life Science Invest Rising Star Awards in 2021 in the MedTech/Diagnostics category. In 2022, RESPINOR received a Seal of Excellence from the EU Commission. RESPINOR has successfully completed clinical feasibility studies in Europe (France and Norway) for the first target segment, mechanical ventilation, with technical proof of concept and proof of principle confirmed. RESPINOR is currently in the process of finalizing the clinical evidence study, DE-RISK WF II Study in France and Norway, which will be the basis for the regulatory CE mark and FDA submission, with planned DXT launch by Q4-2024. See more on: www.respinor.com
For more information, please contact:
Trude Tingvoll, CEO/VD
RESPINOR AS/RESPINOR AB